display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced UC (mUC) - 1st Line (L1)metastatic/advanced UC (mUC) - 2nd Line (L2)metastatic/advanced UC (mUC) - maintenance (M)muscular invasive bladder cancer (MIBC)
mUC - L1 - all populationmUC - L1 - PDL1 positivemUC - L2 - all populationmUC - L2 - PDL1 positivemUC - M - all populationmUC - M - PDL1 positiveMIBC - NA - all populationMIBC - NA - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMvigor-130 ... IMvigor-211 ... IMvigor-211 ... IMvigor-211 ... IMvigor-010
atezolizumab plus SoC IMvigor-130 ...
avelumab based treatment
avelumab alone JAVELIN Bladder 100 ... JAVELIN Bladder 100 ...
durvalumab based treatment
durvalumab alone DANUBE ... DANUBE ...
nivolumab based treatment
nivolumab alone CheckMate 274 ... CheckMate 274 ...
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-361 ... KEYNOTE-045 ... KEYNOTE-045 ...
pembrolizumab plus SoC KEYNOTE-361 ...
Immune checkpoint association
durvalumab plus tremelimumab DANUBE ... DANUBE ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons